Please assess the completion status of the following clinical trial:

Trial Title: A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects with a prior documented definitive diagnosis of hypogonadism as evidenced by previously documented:~  * Hypothalamic, pituitary or testicular disorder or age related idiopathic hypogonadism~ * Screening serum testosterone of less than or equal to 300 ng/dL (based on the average of two morning samples taken at least 30 minutes apart)~* Were currently receiving treatment for hypogonadism in accordance with approved labelling, or in the Investigator's opinion are eligible to receive such treatment~* Body Mass Index (BMI) \< 35.0 kg/m\^2~* Haemoglobin levels at screening greater than or equal to 11.5 g/dL~* Adequate venous access on left or right arm to allow collection of a number of samples by venipuncture~* Ability to communicate with the trial staff, understand the Trial Information Sheet and sign the Written Informed Consent Forms; willing to follow the Protocol requirements and comply with Protocol restrictions and procedures~Exclusion Criteria:~* Current use of long acting testosterone injectables such as Nebido®~* Any significant history of allergy and/or sensitivity to the drug products or their excipients, including any history of sensitivity to testosterone and/or sunscreens~* Any clinically significant chronic illness or finding on screening physical exam and/or laboratory testing that makes it undesirable for the Investigator to enrol the trial subject in the trial and/or that in the Investigator's opinion, would interfere with the trial objectives or safety of the subject~* Chronic skin disorder (e.g. eczema, psoriasis) likely to interfere with transdermal drug absorption~* Men with suspected reversible hypogonadism~* Any man in whom testosterone therapy was contraindicated, which included those with:~  * Known or suspected carcinoma (or history of carcinoma) of the prostate or clinically significant symptoms of benign prostatic hyperplasia and/or clinically significant symptoms of lower urinary obstruction and International Prostate Symptom Scores (IPSS) scores of greater than or equal to 19~ * Known or suspected carcinoma (or history of carcinoma) of the breast~ * Severe liver disease (i.e. cirrhosis, hepatitis or liver tumours or liver function tests \>2 times the upper limit of the normal range values)~ * Active deep vein thrombosis, thromboembolic disorders or a documented history of these conditions~ * Current significant cerebrovascular or coronary artery disease~ * Untreated sleep apnoea~ * Haematocrit of \> 51~ * Untreated moderate to severe depression~* Men with clinically significant prostate exam (such as irregularities or nodules palpated) or clinically significant elevated serum Prostate Specific Antigen (PSA) levels (\>4 ng/mL), or age adjusted reference range of PSA values~* Current or history of drug or alcohol abuse (more than 4 standard drinks per day and/or abnormal liver function tests \>2 times the upper limit of the normal range values)~* Men taking concomitant medications (prescribed, over-the-counter or complementary) that would affect sex hormone binding globulin (SHBG) or testosterone concentrations or metabolism, warfarin, insulin, opiates, Gonadotropin-releasing hormone (GnRH), 5 alpha reductase inhibitors, propanolol, oxyphenbutazone, corticosteroids (except for physiological replacement doses), estradiol~* Men involved in sport in which there is screening for anabolic steroids~* Men with uncontrolled diabetes (haemoglobin A1c \[HbA1c\] greater than or equal to 10%)~* Men currently taking any investigational product, or have received an investigational product within 28 days prior to screening or 5 half-lives~* Any contraindication to blood sampling~* Subjects intending to have any surgical procedure during the course of the trial~* Subjects with a partner of child bearing potential who are not willing to use adequate contraception for the duration of the trial~* Subjects whose partners are pregnant

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Testosterone MD-Lotion (Type: EXPERIMENTAL): Participants received Testosterone Metered Dose (MD)-Lotion for 120 days. Participants started by receiving 3.0 mL (60 mg) of 2% Testosterone MD-Lotion, and based upon restoration to eugonadal levels, may have had their dose of testosterone adjusted upwards or downwards on Days 45 and 90.~Doses could be titrated to one of the following:~1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied daily by 1 dose to the axilla (1.5 mL to one axilla).~3.0 mL (60 mg) of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to each axilla).~4.5 mL (90 mg) of 2% Testosterone MD-Lotion applied daily by 3 doses to the axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).~6.0 mL (120 mg) of 2% Testosterone MD-Lotion applied daily by 4 doses to the axilla (2 x 1.5 mL to each axilla).

Based on this trial design, predict the completion outcome and termination type (if applicable).